FEATURED NEWS
NEWS: A MULTIVALENT mRNA-LNP VACCINE PROTECTS AGAINST CLOSTRIDIOIDES DIFFICILE INFECTION (OCT 2024)
Congratulations to Ying Tam and Mitch Beattie, co-authors of a recent study featured in Science. They collaborated with scientists from the Perelman School of Medicine at the University of Pennsylvania on a multivalent mRNA–lipid nanoparticle vaccine to protect vulnerable individuals against the toxigenic bacterium C. difficile. C. difficile causes disease in all parts of the world, and in Western countries, it represents one of the most common infections found in hospitals and long-term care facilities. Click to read more info.
NEWS: BIVALENT NOROVIRUS mRNA VACCINE ELICITS CELLULAR AND HUMORAL RESPONSES THAT MEDIATE VIRAL NEUTRALIZATION AND PROTECTION AGAINST THE MOST PREVALENT VIRUS VARIANT IN A NOROVIRUS INFECTION MODEL (OCT 2024)
Congratulations to Ying Tam and Barb Mui, co-authors of a recent study featured in NPJ Vaccines. They collaborated with scientists from the Perelman School of Medicine at the University of Pennsylvania on research on a proof of concept bivalent modified-nucleoside mRNA-LNP vaccine based on VP1 capsid sequences from two norovirus variants that can stimulate an immunogenic response in vivo to neutralize the virus and prevent viral infection in a model of human gastrointestinal tract infection. Click to read more info.
NEWS: TARGETED TRANSCRIPTIONAL DOWNREGULATON OF MYC USING EPIGENOMIC CONTROLLERS DEMONSTRATES ANTITUMOR ACTIVITY IN HEPATOCELLULAR CARCINOMA MODELS (SEP 2024)
Congratulations to our partner Omega Therapeutics on their recently published data on leveraging their platform for gene regulation based on controlled mRNA-based epigenomic modulation of Insulated Genomic Domains to selectively and durably downregulate expression of the MYC gene, an important regulator of tumour cells and tumour microenvironment, including hepatocellular carcinoma. Click to read more info.